GGT and ChaC1 modulators derived from natural extracts have been explored
To date, incretin-based approaches for obesity management appear as the most promising and rapidly developing (Supplementary Table 1), with innovations such as once-weekly (OW) injectable triple GIPR/GCGR/GLP-1R agonist retatrutide (LY3437943), cagrilintide (long-acting amylin analogue)/semaglutide 2.4 mg (CagriSema) combination, GCGR/GLP-1R dual agonists, high-dose oral semaglutide, and oral non-peptide GLP-1 receptor agonist orforglipron, with relevant implications in terms of patients compliance and environmental sustainability
Thermoscopic findings include asymmetric perifollicular pigmentation, homo genius areas with obliteration of follicular openings, increased vascularity, red or dark rhomboidal structures, annular granular pattern, gray dots and slate gray globules
10.1165/rcmb.2013-0523OC 2 Al-KhamiA
These figures were created with BioGDP.com
K.JavorskL.PourovJ.et al (2021)